In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

As CLL progresses and treatment is required, many treatment options are available. Treatments may be individualized and based ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

Giving blood could have some surprising benefits, including protecting against leukaemia, heart attacks and high iron levels ...

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

Wael Gamal et al, Mitigating T-Cell Mitochondrial Dysfunction in CLL to Augment CAR T-Cell Therapy: Evaluation in an Immunocompetent Model, Blood Advances (2025). DOI: 10.1182/bloodadvances.2024014822 ...